First global guidance for HPV vaccination for cervical cancer prevention

March 17, 2017
High grade dysplasia (carcinoma in situ) in the uterine cervix. The abnormal epithelium is extending into a mucus gland to the left of centre. This disease can progress to invasive cancer (squamous cell carcinoma) of the cervix. Credit: Haymanj/public domain

The American Society of Clinical Oncology (ASCO) today issued a clinical practice guideline on human papillomavirus (HPV) vaccination for the prevention of cervical cancer. This is the first guideline on primary prevention of cervical cancer that is tailored to multiple regions of the world with different levels of socio-economic and structural resource settings, offering evidence-based guidance to health care providers worldwide.

The guideline includes specific recommendations according to four levels of resource settings: basic, limited, enhanced and maximal. The levels pertain to financial resources of a country or region, as well as the development of its health system—including personnel, infrastructure and access to services. The guideline complements ASCO's two other global, resource-stratified guidelines on cervical cancer, also stratified to these four levels of resources.1,2

Key guideline recommendations:

In all environments and independent of the resource settings, two doses of human papillomavirus vaccine are recommended for girls ages 9 to 14 years, with an interval of at least 6 months and up to 12 to 15 months between doses.

Girls who are HIV positive should receive three doses.

For maximal and enhanced resource settings:

  • If girls are 15 years or older and have received their first dose before age 15, they may complete the two-dose series;
  • If they have not received the first dose before age 15, they should receive three doses;
  • In both scenarios vaccination may be given through age 26 years.

For limited and basic resource settings: if sufficient resources remain after vaccinating girls 9 to 14 years, girls who received one dose may receive additional doses between ages 15 and 26 years.

Vaccination of boys: in all settings, boys may be vaccinated, if there is at least a 50% coverage in priority female target population, sufficient resources, and such vaccination is cost effective.

Cervical cancer is the fourth most common cancer among women worldwide, with less developed regions suffering a disproportionate burden from the disease. In fact, 85% of cervical cancer diagnoses and 87% of cervical cancer deaths occur in less developed regions, including parts of Africa and Latin America.

"Because resource availability varies widely, both among and within countries, we need to adjust strategies to improve access to HPV vaccination everywhere," said Silvia de Sanjosé, MD, PhD, co-chair of the Expert Panel that developed the guideline and head of the Cancer Epidemiology Research Program at Institut Català d'Oncologia in Barcelona, Spain. "This guideline is unique in offering cervical cancer vaccination recommendations that can be adapted to different resource levels and we expect it to have a major impact on the global health community."

HPV infection causes virtually all cervical cancers in the world. Although it may also lead to genital warts and certain other cancers, cervical cancer is by far the most common severe condition related to HPV infection. Unlike other existing HPV vaccination guidelines, ASCO's guideline focuses on the use of HPV vaccination specifically for the prevention of .

"Although HPV vaccine has been around for more than a decade, the uptake of the vaccine has been less than ideal in many places, including in high-resource countries such as the United States," said Silvina Arrossi, PhD, co-chair of the Expert Panel that developed the guideline and an official and researcher at the Instituto Nacional del Cancer in Buenos Aires, Argentina. "As an organization of cancer doctors, ASCO continues to endorse HPV vaccination programs and efforts to help spare more women around the world from this very difficult cancer."

Guideline Methodology

The guideline recommendations were developed by a multinational and multidisciplinary panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts, including some of the world's foremost research leaders on HPV and HPV vaccines.

The Expert Panel reviewed relevant literature published from 1966 to 2015, including systematic reviews, existing guidelines, and cost-effective analyses. This guideline reinforces selected recommendations offered in the World Health Organization (WHO) guideline, Centers for Disease Control and Prevention (CDC) guidelines, National Advisory Committee on Immunization guideline (Canadian), German guidelines, and Immunise Australia guideline.

Explore further: American Cancer Society endorses HPV vaccine recommendations from CDC

More information: The Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline was published today in the Journal of Global Oncology, and is available at www.asco.org/rs-cervical-cance … imary-prev-guideline along with supplementary materials.

1. Jeronimo J, et al. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology - published online before print October 28, 2016

2. Chuang LT, et al. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology 2, no. 5 (October 2016) 311-340.

Related Stories

American Cancer Society endorses HPV vaccine recommendations from CDC

July 19, 2016
The American Cancer Society (ACS) has endorsed HPV vaccination recommendations from the CDC's Advisory Committee on Immunization Practices (ACIP), the principal source of guidance on U.S. immunization policy. The ACS's updated ...

American Cancer Society endorses two-dose regimen for HPV vaccination

February 7, 2017
The American Cancer Society has endorsed updated recommendations on human papillomavirus (HPV) vaccination from the Advisory Committee on Immunization Practices (ACIP) supporting a two-dose schedule for boys and girls who ...

Study finds not all women get appropriate care for cervical cancer

March 2, 2017
Women with locally advanced cervical cancer whose treatment follows national guidelines for care have better survival, regardless of race, ethnicity or stage of cancer.

Recommendations for secondary prevention of cervical cancer

October 25, 2016
(HealthDay)—In a Clinical Practice Guideline published online Oct. 12 in the Journal of Global Oncology, recommendations are presented for the secondary prevention of cervical cancer.

HPV vaccine reduced cervical abnormalities in young women

July 4, 2016
Young women who received the human papillomavirus (HPV) vaccine through a school-based program had fewer cervical cell anomalies when screened for cervical cancer, found a new study in CMAJ (Canadian Medical Association Journal).

Screening, HPV vaccine can prevent cervical cancer: FDA

February 8, 2017
(HealthDay)—Women can reduce their risk of cervical cancer through vaccination and screening, the U.S. Food and Drug Administration says.

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Cave_Man
not rated yet Mar 18, 2017
Hasn't it been proven already that the HPV vaccine is a huge fail and harms many people more so than helping?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.